VolitionRx Announces Study Results Showing NuQ ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
نویسنده
چکیده
NAMUR, Belgium, April 20, 2016 /PRNewswire/ -VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers at 73% specificity1. The study was conducted in collaboration with the Surrey Cancer Research Institute at the University of Surrey in the UK. The results are being presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
منابع مشابه
What is the most appropriate test in detecting prostate cancer in patients with intermediate prostate specific antigen levels?
Abstract Background: Regarding the variety of tests present for detecting and also screening prostate cancer and also bearing in mind the advantages and disadvantages of these tests we decided to re-evaluate these tests (total prostate specific antigen and all of its modifications) in detecting prostate cancer in men with intermediate serum PSAlevels. Methods: Following a cross se...
متن کاملEvaluation of Plasma Interleukin-8 Concentration in Patients with Prostate Cancer and Benign Prostate Hyperplasia
Background: Prostate specific antigen (PSA) has been used as a screening test for the early detection of prostate cancer (PC) for many years. Although the introduction of PSA test led to a considerable increase in reported prostate cancer cases, there is still some controversy over the sensitivity and specificity of this marker in distinguishing PC patients from those with benign prostate hyper...
متن کاملAssessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening
Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...
متن کاملProstate Cancer Screening in Middle-Aged and Older American Men: Combined Effects of Ethnicity and Years of Schooling
Background: Prostate cancer screening is more commonly utilized by highly educated people. As shown by marginalization-related diminished returns (MDRs), the effects of socioeconomic status (SES) such as education on the health outcomes are considerably smaller for ethnic minorities than for Whites. The role of MDRs as a source of ethnic health disparities is, however, still un...
متن کاملمحدوده مرجع ویژه سن برای آنتیژن سرمی اختصاصی پروستات (PSA) در مردان ایرانی
Background: Prostate-Specific Antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is the best marker for early diagnosis of prostate cancer. Since age and race are affecting PSA levels, determining age-specific reference ranges of PSA in every community is necessary for increasing the efficiency rate of PSA. The aim of the present study was to evaluate the normal distributi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017